SA-4-1BBL/MPL作为一种新型免疫佐剂平台用于对抗癌症。
SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.
作者信息
Srivastava Abhishek K, Yolcu Esma S, Dinc Gunes, Sharma Rajesh K, Shirwan Haval
机构信息
Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD USA.
Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA.
出版信息
Oncoimmunology. 2015 Jul 1;5(1):e1064580. doi: 10.1080/2162402X.2015.1064580. eCollection 2016.
Abstract
Practical experience with cancer vaccines combined with accumulated knowledge of the complex interactions between cancer and immune system rationalize the combinatorial use of immune adjuvants for better efficacy. We recently described a novel adjuvant system based on the costimulatory SA-4-1BBL and TLR4 agonist MPL that has desired therapeutic and safety profiles.
摘要
癌症疫苗的实践经验，结合对癌症与免疫系统之间复杂相互作用的积累知识，使免疫佐剂的联合使用具有更好疗效成为合理选择。我们最近描述了一种基于共刺激分子SA-4-1BBL和TLR4激动剂MPL的新型佐剂系统，该系统具有理想的治疗效果和安全性。
相似文献
1
SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.
Oncoimmunology. 2015 Jul 1;5(1):e1064580. doi: 10.1080/2162402X.2015.1064580. eCollection 2016.
2
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
Cancer Res. 2014 Nov 15;74(22):6441-51. doi: 10.1158/0008-5472.CAN-14-1768-A. Epub 2014 Sep 24.
3
Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Vaccine. 2014 Sep 3;32(39):5035-40. doi: 10.1016/j.vaccine.2014.07.015. Epub 2014 Jul 18.
4
A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4 T and Natural Killer Cells.
Cancer Res. 2019 Feb 15;79(4):783-794. doi: 10.1158/0008-5472.CAN-18-2401.
5
Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Adv Exp Med Biol. 2010;667:111-23. doi: 10.1007/978-1-4419-1603-7_10.
6
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Expert Rev Vaccines. 2003 Apr;2(2):219-29. doi: 10.1586/14760584.2.2.219.
7
A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model.
Cancers (Basel). 2019 Jan 15;11(1):96. doi: 10.3390/cancers11010096.
8
Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Vaccine. 2019 Sep 10;37(38):5708-5716. doi: 10.1016/j.vaccine.2019.07.103. Epub 2019 Aug 12.
9
Current perspectives of SA-4-1BBL in immune modulation during cancer.
Exp Ther Med. 2018 Mar;15(3):2699-2702. doi: 10.3892/etm.2018.5729. Epub 2018 Jan 9.
10
4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
Cell Mol Immunol. 2008 Oct;5(5):379-84. doi: 10.1038/cmi.2008.47.
引用本文的文献
1
A Unique Combination of Mn and Aluminum Adjuvant Acted the Synergistic Effect.
Can J Infect Dis Med Microbiol. 2024 Apr 17;2024:7502110. doi: 10.1155/2024/7502110. eCollection 2024.
2
Als3-Th-cell-epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice.
Immun Inflamm Dis. 2021 Sep;9(3):971-983. doi: 10.1002/iid3.456. Epub 2021 May 19.
3
Therapeutic Vaccines for HPV-Associated Malignancies.
Immunotargets Ther. 2020 Oct 7;9:167-200. doi: 10.2147/ITT.S273327. eCollection 2020.
4
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018.
5
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017.
6
Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.
Nanomedicine (Lond). 2017 Dec;12(23):2693-2706. doi: 10.2217/nnm-2017-0254. Epub 2017 Nov 3.
7
The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Oncotarget. 2017 Jul 11;8(28):45951-45964. doi: 10.18632/oncotarget.17504.
本文引用的文献
1
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
Cancer Res. 2014 Nov 15;74(22):6441-51. doi: 10.1158/0008-5472.CAN-14-1768-A. Epub 2014 Sep 24.
2
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340.
3
CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
PLoS One. 2013 Sep 16;8(9):e73145. doi: 10.1371/journal.pone.0073145. eCollection 2013.
4
Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
PLoS One. 2012;7(11):e48463. doi: 10.1371/journal.pone.0048463. Epub 2012 Nov 8.
5
SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
PLoS One. 2012;7(8):e42459. doi: 10.1371/journal.pone.0042459. Epub 2012 Aug 1.
6
4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Cancer Res. 2010 May 15;70(10):3945-54. doi: 10.1158/0008-5472.CAN-09-4480. Epub 2010 Apr 20.
7
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Cancer Res. 2009 May 15;69(10):4319-26. doi: 10.1158/0008-5472.CAN-08-3141. Epub 2009 May 12.
8
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8.
9
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
J Immunol. 2007 Dec 1;179(11):7295-304. doi: 10.4049/jimmunol.179.11.7295.
10
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
J Clin Invest. 2005 Dec;115(12):3623-33. doi: 10.1172/JCI25947. Epub 2005 Nov 23.
Zotero 插件